ARTICLE

EXPLORING ORAL IMMUNOTHERAPEUTICS IN ONCOLOGY USES SIDE EFFECTS NOVEL APPROACHES CHALLENGES AND FUTURE PROSPECTS

02 Pages : 9-17

http://dx.doi.org/10.31703/gpsr.2024(IX-II).02      10.31703/gpsr.2024(IX-II).02      Published : Jun 2024

Exploring Oral Immunotherapeutics in Oncology: Uses, Side Effects Novel Approaches, Challenges, and Future Prospects

    Immunotherapy is a medical intervention in which certain immune system components are used to combat disease. Usually, immunotherapy works by helping the body fight off the offending substance by modifying it as well as boosting the immune system. Biologic therapy or biotherapy are additional terms for certain forms of immunotherapy. Different advances and novel approaches have been studied such as cancer vaccines, immune checkpoint inhibitors, monoclonal antibodies, etc. Oral immunotherapeutics are used in a variety of solid tumors and hematological malignancies but still, these immunotherapeutics have their own limitations and adverse effects. Management of these side effects and optimization of therapeutic benefits remains a challenge. Moreover, challenges such as patient selection, dose optimization, and medication resistance are major issues that hinder the widespread use of oral immunotherapeutics. However, the future of oral immunotherapy in oncology seems to be promising due to the new advancements and research done. New advancements hold the potential to revolutionize cancer therapy.

    Cancer, ADCs, Immunotherapeutic, Oral Immunotherapeutic, Combination Therapies, Targeted Therapies, Adverse Effects, Challenges, Advancement in Immunotherapy
    (1) Kalya Ahmad Sandhu
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
    (2) Asawar Yameen
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
    (3) Naima Zafar
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
    (4) Hira Ali
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
    (5) Usama Abid
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
    (6) Mishkaat Raza
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
  • Bai, R., Chen, N., Li, L., & Cui, J. (2021). A brand new era of cancer immunotherapy: breakthroughs and challenges. Chinese Medical Journal, 134(11), 1267–1275. https://doi.org/10.1097/cm9.0000000000001490

  • Baker, D., Herrod, S. S., Alvarez-Gonzalez, C., Giovannoni, G., & Schmierer, K. (2017). Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of Alemtuzumab. JAMA Neurology, 74(8), 961. https://doi.org/10.1001/jamaneurol.2017.0676
  • Cohen, R. B. (2003). Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clinical Colorectal Cancer, 2(4), 246–251. https://doi.org/10.3816/ccc.2003.n.006
  • Coop, C. A., & Tankersley, M. S. (2008). Patient perceptions regarding local reactions from allergen immunotherapy injections. Annals of Allergy Asthma & Immunology, 101(1), 96–100. https://doi.org/10.1016/s1081-1206(10)60841-1
  • Disis, M. L. (2014). Mechanism of action of immunotherapy. Seminars in Oncology, 41, S3–S13. https://doi.org/10.1053/j.seminoncol.2014.09.004
  • Dobosz, P., & Dzieciątkowski, T. (2019). The intriguing history of cancer immunotherapy. Frontiers in Immunology, 10. https://doi.org/10.3389/fimmu.2019.02965
  • Hu, Y., Turner, M. J., Shields, J., Gale, M. S., Hutto, E., Roberts, B. L., Siders, W. M., & Kaplan, J. M. (2009). Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology, 128(2), 260–270. https://doi.org/10.1111/j.1365-2567.2009.03115.x
  • Karmakar, S., Dhar, R., Seethy, A., Singh, S., Pethusamy, K., Srivastava, T., Talukdar, J., & Rath, G. (2021). Cancer immunotherapy: Recent advances and challenges. Journal of Cancer Research and Therapeutics, 17(4), 834. https://doi.org/10.4103/jcrt.jcrt_1241_20
  • Klotz, L., Meuth, S. G., & Wiendl, H. (2012). Immune mechanisms of new therapeutic strategies in multiple sclerosis—A focus on alemtuzumab. Clinical Immunology, 142(1), 25–30. https://doi.org/10.1016/j.clim.2011.04.006
  • National Cancer Institute. (2019). Monoclonal antibodies. U.S. Department of Health and Human Services. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies
  • Peterson, C., Denlinger, N., & Yang, Y. (2022). Recent advances and challenges in cancer immunotherapy. Cancers, 14(16), 3972. https://doi.org/10.3390/cancers14163972
  • Peterson, C., Denlinger, N., & Yang, Y. (2022b). Recent advances and challenges in cancer immunotherapy. Cancers, 14(16), 3972. https://doi.org/10.3390/cancers14163972
  • Thorpe, P. E., Ross, W. C. J., Cumber, A. J., Hinson, C. A., Edwards, D. C., & Davies, A. J. S. (1978). Toxicity of diphtheria toxin for lymphoblastoid cells is increased by conjugation to antilymphocytic globulin. Nature, 271(5647), 752–755. https://doi.org/10.1038/271752a0
  • Turner, M. J., LaMorte, M. J., Chretien, N., Havari, E., Roberts, B. L., Kaplan, J. M., & Siders, W. M. (2013). Immune status following alemtuzumab treatment in human CD52 transgenic mice. Journal of Neuroimmunology, 261(1–2), 29–36. https://doi.org/10.1016/j.jneuroim.2013.04.018
  • Umapathy, V. R., Natarajan, P. M., & Swamikannu, B. (2023). Review of the role of nanotechnology in overcoming the challenges faced in oral cancer diagnosis and treatment. Molecules, 28(14), 5395. https://doi.org/10.3390/molecules28145395
  • Vasileiou, M., Papageorgiou, S., & Nguyen, N. P. (2023). Current advancements and future perspectives of immunotherapy in breast cancer treatment. Immuno, 3(2), 195–216. https://doi.org/10.3390/immuno3020013
  • Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020). A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nature Reviews. Immunology, 20(11), 651–668. https://doi.org/10.1038/s41577-020-0306-5
  • Weth, F. R., Hoggarth, G. B., Weth, A. F., Paterson, E., White, M. P. J., Tan, S. T., Peng, L., & Gray, C. (2023). Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy. British Journal of Cancer, 130(5), 703–715. https://doi.org/10.1038/s41416-023-02502-9
  • Yamaizumi, M., Mekada, E., Uchida, T., & Okada, Y. (1978b). One molecule of diphtheria toxin fragment a introduced into a cell can kill the cell. Cell, 15(1), 245–250. https://doi.org/10.1016/0092-8674(78)90099-5

Cite this article

    APA : Sandhu, K. A., Yameen, A., & Zafar, N. (2024). Exploring Oral Immunotherapeutics in Oncology: Uses, Side Effects Novel Approaches, Challenges, and Future Prospects. Global Pharmaceutical Sciences Review, IX(II), 9-17. https://doi.org/10.31703/gpsr.2024(IX-II).02
    CHICAGO : Sandhu, Kalya Ahmad, Asawar Yameen, and Naima Zafar. 2024. "Exploring Oral Immunotherapeutics in Oncology: Uses, Side Effects Novel Approaches, Challenges, and Future Prospects." Global Pharmaceutical Sciences Review, IX (II): 9-17 doi: 10.31703/gpsr.2024(IX-II).02
    HARVARD : SANDHU, K. A., YAMEEN, A. & ZAFAR, N. 2024. Exploring Oral Immunotherapeutics in Oncology: Uses, Side Effects Novel Approaches, Challenges, and Future Prospects. Global Pharmaceutical Sciences Review, IX, 9-17.
    MHRA : Sandhu, Kalya Ahmad, Asawar Yameen, and Naima Zafar. 2024. "Exploring Oral Immunotherapeutics in Oncology: Uses, Side Effects Novel Approaches, Challenges, and Future Prospects." Global Pharmaceutical Sciences Review, IX: 9-17
    MLA : Sandhu, Kalya Ahmad, Asawar Yameen, and Naima Zafar. "Exploring Oral Immunotherapeutics in Oncology: Uses, Side Effects Novel Approaches, Challenges, and Future Prospects." Global Pharmaceutical Sciences Review, IX.II (2024): 9-17 Print.
    OXFORD : Sandhu, Kalya Ahmad, Yameen, Asawar, and Zafar, Naima (2024), "Exploring Oral Immunotherapeutics in Oncology: Uses, Side Effects Novel Approaches, Challenges, and Future Prospects", Global Pharmaceutical Sciences Review, IX (II), 9-17
    TURABIAN : Sandhu, Kalya Ahmad, Asawar Yameen, and Naima Zafar. "Exploring Oral Immunotherapeutics in Oncology: Uses, Side Effects Novel Approaches, Challenges, and Future Prospects." Global Pharmaceutical Sciences Review IX, no. II (2024): 9-17. https://doi.org/10.31703/gpsr.2024(IX-II).02